Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products

Executive Summary

The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.


Related Content

Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA Warning For Ariad’s Iclusig, While CHCs Get The Benefit Of The Doubt
EMA Knocks Back Pfizer’s Xeljanz For Rheumatoid Arthritis and Otsuka’s Delamanid For TB
Generational Differences? The Risk Of VTE With Oral Contraceptives
France Suspends Bayer Diane 35: Post-Mediator Strictness Or Prelude To Broad Withdrawal?
Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
EMA Moves To Reassure Europe Over Combined Contraceptives
Blood Clot Risk Of Drospirenone Products Remains Open Issue For FDA
European Pharmacovigilance Update Still Causing Concern
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts